The increasing use of technology for treating type 1 diabetes (T1D) has improved glycemic control; however, it hasn’t eliminated the risk for diabetic ketoacidosis (DKA). In fact, without early recognition, insulin pump malfunctions can directly lead to DKA. Currently, patients test ketones at home using urine test strips that measure acetoacetate (the primary ketone body) and fingerstick blood monitors that measure beta-hydroxybutyrate (BHB, the primary circulating ketone body).
A wearable device that continuously measures interstitial BHB levels, similar to how continuous glucose monitors (CGM) track glucose, has been shown as feasible and offers the potential for preventing DKA.
Abbott Diabetes Care is currently developing a two-in-one wearable sensor that combines CGM and continuous ketone monitoring (CKM).
At the…